Ignite Creation Date:
2024-05-06 @ 10:25 AM
Last Modification Date:
2024-10-26 @ 12:29 PM
Study NCT ID:
NCT03252249
Status:
COMPLETED
Last Update Posted:
2024-05-03
First Post:
2017-08-09
Brief Title:
Duration of Dual Anti-Platelet Therapy DUAL-ACS
Sponsor:
University of Edinburgh
Organization:
University of Edinburgh
Study Overview
Official Title:
Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome there remains major uncertainty regarding the optimal duration of therapy Recent evidence suggests that shorter durations of dual anti-platelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations We here propose an international randomised controlled trial of 18318 patients with type 1 myocardial infarction allocated to differing durations of dual anti-platelet therapy We will use electronic health record linkage to track duration of therapy and clinical outcomes in a real-world real-time efficient and highly cost-effective trial This has the potential to define treatment duration settle a major outstanding international controversy and influence modern cardiology practice across the world
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None